Free Trial

TScan Therapeutics (TCRX) Competitors

TScan Therapeutics logo
$1.72 +0.03 (+1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.73 +0.01 (+0.58%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TCRX vs. SLDB, ATXS, NBTX, FULC, CGEM, KMDA, INBX, AURA, ADCT, and PRTC

Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), Aura Biosciences (AURA), ADC Therapeutics (ADCT), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

TScan Therapeutics vs. Its Competitors

TScan Therapeutics (NASDAQ:TCRX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

TScan Therapeutics currently has a consensus target price of $7.80, suggesting a potential upside of 353.49%. Solid Biosciences has a consensus target price of $15.00, suggesting a potential upside of 177.26%. Given TScan Therapeutics' higher possible upside, equities analysts plainly believe TScan Therapeutics is more favorable than Solid Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Solid Biosciences
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.09

Solid Biosciences has higher revenue and earnings than TScan Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$2.82M34.61-$127.50M-$1.09-1.58
Solid Biosciences$8.09M52.07-$124.70M-$2.80-1.93

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 4.4% of TScan Therapeutics shares are owned by insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TScan Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Solid Biosciences has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Solid Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. TScan Therapeutics' return on equity of -63.33% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-1,964.88% -63.33% -40.19%
Solid Biosciences N/A -69.70%-56.74%

In the previous week, Solid Biosciences had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.89 beat Solid Biosciences' score of 1.04 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TScan Therapeutics Very Positive
Solid Biosciences Positive

Summary

Solid Biosciences beats TScan Therapeutics on 10 of the 17 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRX vs. The Competition

MetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$95.90M$3.12B$5.73B$10.31B
Dividend YieldN/A2.36%5.90%4.63%
P/E Ratio-1.5821.1675.8626.51
Price / Sales34.61446.35528.74123.58
Price / CashN/A45.4037.1760.46
Price / Book0.409.6212.796.29
Net Income-$127.50M-$53.28M$3.28B$270.51M
7 Day Performance-6.52%0.31%0.22%2.15%
1 Month Performance-4.44%4.58%4.61%6.35%
1 Year Performance-70.03%9.24%68.33%25.48%

TScan Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
3.2873 of 5 stars
$1.72
+1.8%
$7.80
+353.5%
-70.6%$95.90M$2.82M-1.58100Positive News
SLDB
Solid Biosciences
3.1018 of 5 stars
$5.13
-6.7%
$15.00
+192.4%
-30.8%$428.28M$8.09M-1.83100Positive News
Analyst Downgrade
ATXS
Astria Therapeutics
2.8498 of 5 stars
$7.43
-1.2%
$29.00
+290.3%
-33.8%$424.39MN/A-3.7030Positive News
NBTX
Nanobiotix
0.6268 of 5 stars
$8.71
+0.1%
$8.00
-8.2%
+88.3%$417.11M$39.18M0.00100Upcoming Earnings
Short Interest ↑
Gap Up
FULC
Fulcrum Therapeutics
2.6257 of 5 stars
$7.27
-5.1%
$7.57
+4.1%
+122.3%$414.34M$80M-5.96100News Coverage
Positive News
Short Interest ↓
CGEM
Cullinan Therapeutics
2.1594 of 5 stars
$6.84
-2.1%
$26.80
+291.8%
-64.6%$412.93MN/A-2.1230
KMDA
Kamada
4.5478 of 5 stars
$7.22
+1.1%
$13.00
+80.1%
+25.1%$410.59M$169.52M21.24360Short Interest ↓
INBX
Inhibrx Biosciences
1.0567 of 5 stars
$29.10
+3.3%
N/A+65.6%$408.20M$200K-2.75166News Coverage
Positive News
AURA
Aura Biosciences
2.0143 of 5 stars
$6.47
-0.2%
$22.00
+240.0%
-40.7%$402.54MN/A-3.3050Positive News
ADCT
ADC Therapeutics
3.1489 of 5 stars
$3.51
-0.8%
$7.75
+120.6%
+3.4%$398.25M$70.84M-2.24310
PRTC
PureTech Health
0.545 of 5 stars
$16.42
+1.2%
N/A-21.6%$391.71M$6.17M0.00100Short Interest ↑

Related Companies and Tools


This page (NASDAQ:TCRX) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners